Overview

Open Label Trial to Assess Iressa in Prostate Cancer Patients

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib